Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin C Bader

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Opinion in Pharmacology|November 21, 2017
Ensuring quality pharmacokinetic analyses in antimicrobial drug development programsElizabeth A Lakota, Justin C Bader, Christopher M Rubino
Clinical Pharmacokinetics|April 30, 2021
Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear ExportJustin C Bader, Albiruni R Abdul Razak, Sharon Shacham, et al.
The Journal of Antimicrobial Chemotherapy|January 6, 2018
We can do better: a fresh look at echinocandin dosingJustin C Bader, Sujata M Bhavnani, David R Andes, et al.
The Journal of Antimicrobial Chemotherapy|January 18, 2018
We can do better: a fresh look at echinocandin dosingJustin C Bader, Sujata M Bhavnani, David R Andes, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2021
Selinexor population pharmacokinetic and exposure-response analyses to support dose optimization in patients with diffuse large B-cell lymphomaHongmei Xu, Hanbin Li, Russ Wada, et al.
Open Forum Infectious Diseases|December 25, 2018
Time for Precision: A World Without Susceptibility BreakpointsJustin C Bader, Elizabeth A Lakota, David R Andes, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2018
Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal ActivityPaul G Ambrose, Brian D VanScoy, John Adams, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2018
<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse ModelMiao Zhao, Alexander J Lepak, Brian VanScoy, et al.
Antimicrobial Agents and Chemotherapy|December 19, 2018
Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniaeAlexander J Lepak, Miao Zhao, Qingmei Liu, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Pharmacology|November 21, 2017
Ensuring quality pharmacokinetic analyses in antimicrobial drug development programsElizabeth A Lakota, Justin C Bader, Christopher M Rubino
Clinical Pharmacokinetics|April 30, 2021
Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear ExportJustin C Bader, Albiruni R Abdul Razak, Sharon Shacham, et al.
The Journal of Antimicrobial Chemotherapy|January 6, 2018
We can do better: a fresh look at echinocandin dosingJustin C Bader, Sujata M Bhavnani, David R Andes, et al.
The Journal of Antimicrobial Chemotherapy|January 18, 2018
We can do better: a fresh look at echinocandin dosingJustin C Bader, Sujata M Bhavnani, David R Andes, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2021
Selinexor population pharmacokinetic and exposure-response analyses to support dose optimization in patients with diffuse large B-cell lymphomaHongmei Xu, Hanbin Li, Russ Wada, et al.
Open Forum Infectious Diseases|December 25, 2018
Time for Precision: A World Without Susceptibility BreakpointsJustin C Bader, Elizabeth A Lakota, David R Andes, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2018
Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal ActivityPaul G Ambrose, Brian D VanScoy, John Adams, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2018
<i>In Vivo</i> Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse ModelMiao Zhao, Alexander J Lepak, Brian VanScoy, et al.
Antimicrobial Agents and Chemotherapy|December 19, 2018
Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniaeAlexander J Lepak, Miao Zhao, Qingmei Liu, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Pageof 2